TY - JOUR
T1 - Renal cell carcinoma with early skin metastasis and partial response on tyrosine kinase inhibitor
T2 - A case report
AU - Hamid, Agus Rizal Ardy Hariandy
AU - Rustandi, Reginald
AU - Matondang, Sahat
AU - Saraswati, Meilania
AU - Sari, Lenny
AU - Panigoro, Sonar Soni
N1 - Funding Information:
This work was supported by Universitas Indonesia for funding this research through PUTI Grant with contract number NKB-2281/UN2.RST/HKP.05.00/2020 .
Publisher Copyright:
© 2022 The Authors
PY - 2022/5
Y1 - 2022/5
N2 - Introduction and importance: Renal cell carcinoma (RCC) skin metastasis is a rare disease. However, there are no data on the effect of a Tyrosine Kinase Inhibitor (TKI) on its treatment. Case presentation: A 54-year-old male patient with renal cell carcinoma developed subcutaneous metastasis three months after radical nephrectomy and there was no discoloration or pain. Furthermore, an excision biopsy confirmed the metastatic lesion, and pazopanib was initiated as a treatment method. After 1-month of treatment, the patient developed ulceration and subsided after treatment was stopped. Similarly, a follow-up PET scan was performed almost a year after stopping the treatment, which showed improvement over metastatic pulmonary lesions. Clinical discussion: Renal cell carcinoma (RCC) major metastases were observed in pulmonary, costal, and skin. Tumor burden and location of metastasis influences progression free-survival of RCC patients treated with TKI. Conclusion: In this case, TKI treatment showed a long-term partial response, despite its lack of continuous therapy.
AB - Introduction and importance: Renal cell carcinoma (RCC) skin metastasis is a rare disease. However, there are no data on the effect of a Tyrosine Kinase Inhibitor (TKI) on its treatment. Case presentation: A 54-year-old male patient with renal cell carcinoma developed subcutaneous metastasis three months after radical nephrectomy and there was no discoloration or pain. Furthermore, an excision biopsy confirmed the metastatic lesion, and pazopanib was initiated as a treatment method. After 1-month of treatment, the patient developed ulceration and subsided after treatment was stopped. Similarly, a follow-up PET scan was performed almost a year after stopping the treatment, which showed improvement over metastatic pulmonary lesions. Clinical discussion: Renal cell carcinoma (RCC) major metastases were observed in pulmonary, costal, and skin. Tumor burden and location of metastasis influences progression free-survival of RCC patients treated with TKI. Conclusion: In this case, TKI treatment showed a long-term partial response, despite its lack of continuous therapy.
KW - Advanced cancer
KW - Chemotherapy
KW - Oncology
KW - Renal cell carcinoma
KW - Skin metastasis
KW - Urology
UR - http://www.scopus.com/inward/record.url?scp=85128466801&partnerID=8YFLogxK
U2 - 10.1016/j.ijscr.2022.107020
DO - 10.1016/j.ijscr.2022.107020
M3 - Article
AN - SCOPUS:85128466801
SN - 2210-2612
VL - 94
JO - International Journal of Surgery Case Reports
JF - International Journal of Surgery Case Reports
M1 - 107020
ER -
